Geulah Livshits
Stock Analyst at Chardan Capital
(4.16)
# 383
Out of 5,090 analysts
241
Total ratings
43.15%
Success rate
17.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $74 | $56.88 | +30.10% | 16 | Nov 26, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $10.18 | +145.58% | 3 | Nov 24, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 | $100.49 | +9.46% | 5 | Nov 13, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $6.40 | +212.50% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $9.21 | +128.01% | 6 | Nov 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 → $26 | $10.70 | +142.99% | 13 | Nov 11, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 | $1.41 | +538.30% | 13 | Nov 10, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $10 → $9 | $3.74 | +140.64% | 7 | Nov 10, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $48 → $26 | $9.61 | +170.55% | 17 | Nov 7, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $20 → $17 | $2.20 | +672.73% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 | $9.35 | +81.82% | 12 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $5.05 | +137.62% | 16 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $5.77 | +159.97% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $234.13 | -6.04% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.32 | +231.33% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.78 | +517.98% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $2.13 | +463.38% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.53 | +1,041.55% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.42 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $8.65 | +373.99% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.55 | +370.59% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $27.70 | +650.90% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.87 | +1,739.08% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $13.16 | +583.89% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.28 | -6.54% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $4.26 | +604.23% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $19.76 | -8.91% | 1 | Oct 27, 2020 |
CRISPR Therapeutics AG
Nov 26, 2025
Maintains: Buy
Price Target: $82 → $74
Current: $56.88
Upside: +30.10%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $10.18
Upside: +145.58%
Palvella Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $110
Current: $100.49
Upside: +9.46%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $6.40
Upside: +212.50%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $9.21
Upside: +128.01%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Buy
Price Target: $25 → $26
Current: $10.70
Upside: +142.99%
Tenaya Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $9
Current: $1.41
Upside: +538.30%
Prime Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.74
Upside: +140.64%
Intellia Therapeutics
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $9.61
Upside: +170.55%
Iovance Biotherapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.20
Upside: +672.73%
Nov 5, 2025
Maintains: Buy
Price Target: $17
Current: $9.35
Upside: +81.82%
Nov 5, 2025
Maintains: Buy
Price Target: $12
Current: $5.05
Upside: +137.62%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $5.77
Upside: +159.97%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $234.13
Upside: -6.04%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.32
Upside: +231.33%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.78
Upside: +517.98%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $2.13
Upside: +463.38%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.53
Upside: +1,041.55%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.42
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $8.65
Upside: +373.99%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.55
Upside: +370.59%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $27.70
Upside: +650.90%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.87
Upside: +1,739.08%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $13.16
Upside: +583.89%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.28
Upside: -6.54%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $4.26
Upside: +604.23%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $19.76
Upside: -8.91%